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Abstract: In the pediatric population, pulmonary hypertension may present as an acute event 
in the setting of lung or cardiac pathology or as a chronic disease, mainly as idiopathic pulmo-
nary hypertension or associated with congenital heart disease. Recently, new pharmacologic 
approaches have demonstrated signiﬁ  cant efﬁ  cacy in the management of adults with pulmonary 
arterial hypertension; these include intravenous epoprostenol, prostacyclin analogs, endothelin 
receptor antagonists and phosphodiesterase type 5 inhibitors. The same treatment strategies 
are currently used in children. There are only few reports of the use of inhaled iloprost in 
pediatrics, only one of which reported the use of chronic inhaled iloprost in a signiﬁ  cant number 
of children. This report showed that 1) the acute pulmonary vasodilator response to inhaled 
iloprost is equivalent to that of inhaled nitric oxide; 2) acute inhalation of iloprost can induce 
bronchoconstriction 3) the addition of inhaled iloprost can reduce the need for intravenous 
prostanoid therapy in some patients; 4) most children tolerated the combination of inhaled 
iloprost and endothelin receptor antagonist or phosphodiesterase inhibitors; 5) Several patients 
had clinical deterioration during chronic inhaled iloprost therapy and required rescue therapy 
with intravenous prostanoids. In this review we will discuss the role of inhaled iloprost in acute 
and chronic pulmonary hypertension in children.
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Introduction
In the pediatric population, pulmonary hypertension may present as an acute event in the 
setting of lung or cardiac disease, for example after cardiopulmonary bypass for correc-
tion of congenital heart disease1 or associated with acute lung injury. A speciﬁ  c form of 
pediatric pulmonary hypertension is persistent pulmonary hypertension of the newborn. 
But pulmonary hypertension also presents as a chronic disease in children.2,3
Chronic pulmonary arterial hypertension is a rare and complex disease character-
ized by vasoconstriction and progressive remodeling of the pulmonary arterial wall 
leading to right ventricular failure and death.4 The pathologic features are similar in 
children and in adults but the spectrum of associated conditions, clinical presentation 
and factors inﬂ  uencing survival differ slightly.2,5,6 The different etiologies are all 
included in the revised classiﬁ  cation of Venice, which was ﬁ  rst mainly produced for 
adult patients.7 The most common etiologies in children after the immediate neonatal 
period are idiopathic, familial or associated with congenital heart disease.
Historically, pulmonary arterial hypertension carried a dismal prognosis in children 
less than 16 years with a median survival of 0.8 years compared to 2.8 years in adults.6 
The role of endothelial dysfunction and the abnormal balance of vasodilator-antimitotic 
(prostacyclin and nitric oxide) versus vasoconstrictor-promitotic (endothelin-1) 
substances shown in adults4 are also true for the pediatric population. We have 
now moved from the belief of pulmonary arterial hypertension as a process driven Vascular Health and Risk Management 2009:5 326
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by vasoconstriction only, to a concept of a disease also 
characterized by proliferation and remodeling.
Recently, new pharmacologic approaches have dem-
onstrated significant efficacy in the management of 
adults with pulmonary arterial hypertension (PAH); these 
include intravenous eproprostenol,8 prostacyclin analogs 
delivered subcutaneously (treprostinil9) or by inhalation 
(iloprost10), endothelin receptor antagonists (bosentan11,12) 
and ambrisentan13) and phosphodiesterase type 5 inhibitors 
(sildenaﬁ  l14). The same treatment strategies are currently 
used in children.2,6,15 In the late 1990s, the development of 
chronic vasodilator therapy including calcium channel block-
ers for acute responders to vasodilator testing and continuous 
intravenous epoprostenol for non-responders has dramati-
cally improved the outcome of children, with some children 
surviving more than 10 years after diagnosis.16
However, the use of continuous intravenous epopro-
stenol17 in children, even if clearly efﬁ  cacious, remains a 
difﬁ  cult approach both for the child and the parents. The 
need for a permanent central line and pump and its associated 
risks of infection, thrombosis and dysfunction lead to the 
development of other delivery approach. In this review, we 
will discuss the rationale of using inhaled iloprost in acute 
and chronic pulmonary hypertension in children as well as 
the potential beneﬁ  t and problems of this therapy.
Iloprost
Prostacyclin is a naturally occurring prostaglandin described 
more than 20 years ago to be a potent antiaggregatory and 
vasodilator agent.18 Prostacyclin is primarily produced by 
the endothelial cells of the vascular intima and acts through 
a speciﬁ  c receptor-mediated activation of membrane-bound 
adenylate cyclase and a consequent increase in intracellular 
cyclic adenosine monophosphate.19
Iloprost is a stable prostacyclin analog, pharmacologically 
similar to epoprostenol, with vasodilatory, vascular remod-
eling and platelet inhibitory properties, but is a more stable 
compound, with an elimination half-life of 20 to 30 minutes.20 
Iloprost exerts its effects via prostacyclin receptors and pro-
mote similar mechanisms to epoprostenol. The biological 
effects of prostacyclin are indeed mediated by binding to a 
group of receptors. The receptors for prostanoids are classi-
ﬁ  ed into DP, IP, EP, FP and TP.21 There are some differences, 
as different analogs seem to activate different subgroups of 
receptors. Iloprost is thought to bind to IP and EP3 receptors, 
but the ﬁ  nal intracellular effect as mentioned is essentially 
through the increase of cAMP via stimulation of guanylate 
cyclase. The transduced biological effects are vasodilation, 
inhibition of platelet activation and aggregation, inhibition 
of leukocytes activation, and adhesion (anti-inﬂ  ammatory 
effects) and antiproliferation. Iloprost has also shown some 
de-remodeling effect in animal studies.22,23
There is extensive experience with its intravenous use in 
different indications including thromboarteritis obliterans24 
or Raynaud phenomenon.25 In general, the doses used are in 
the range of 1 to 10 ng/kg/min compared to doses ranging 
from 10 to 50 μg/kg/min for epoprostenol, but the dosages 
may ﬂ  uctuate.
The main problem related to the intravenous use is the 
lack of selectivity for the pulmonary vascular bed and there-
fore the potential risk of systemic hypotension. To overcome 
the systemic side effects, the inhaled route has been used 
to obtain pulmonary selectivity similarly to inhaled nitric 
oxide. The distance between the alveoli and the smooth 
muscle cell is 10 μm at the most, allowing for easy transfer 
of the inhaled drug. The real barrier to uptake is the vascular 
adventitia itself. A prerequisite is to obtain particles that 
can reach the alveoli, and for this purpose the droplet size 
should range between 2.5 and 5 μm. When administered by 
inhalation iloprost is selective for the pulmonary vasculature, 
inducing a decrease in pulmonary vascular pressure with no 
or minor effects on the systemic circulation. Moreover, it can 
be delivered to only ventilated regions, avoiding the potential 
increase of intrapulmonary shunts by dilating vessels in non-
ventilated areas, as seen with intravenous administration. 
This preferential delivery to well-ventilated regions areas 
improves ventilation perfusion mismatch.26
When prostacyclins are administered intravenously a 
tachyphylaxis phenomenon may appear requiring permanent 
dose escalation. This may be explained by desensitization 
of the IP receptor and/or a saturation of the transporter 
system.27,28 Research has shown that this leads to complete 
loss of vasodilatory response to prostanoids, and this should 
be kept in mind when using prostanoids treatment. This phe-
nomenon may indeed explain the failure of the drug in some 
patients as well as the need of dose escalation.
Adult use of inhaled iloprost
Until recently, chronic treatment with prostacyclin analogs 
in adults has required intravenous or subcutaneous 
administration, with each approach limited by problems such 
as line infections, thrombosis, or site pain. Previous stud-
ies of inhaled iloprost have been performed primarily in 
adult patients.29,30 In one large multicenter, randomized, 
placebo-controlled trial of iloprost therapy for 3 months, 
more patients demonstrated the combined endpoint of at Vascular Health and Risk Management 2009:5 327
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least a 10% improvement in the 6 minute walk distance 
and improvement in NYHA functional class (17% vs 5%; 
p  0.01), and no deterioration or death.10 This trial included 
203 patients with idiopathic pulmonary hypertension, or 
PAH occurring in association with appetite suppressant 
use, inoperable chronic thromboembolic pulmonary hyper-
tension, and connective tissue disease. The 6 minute walk 
distance increased by 36 m in the iloprost-treated patients, 
and increased by 59 m in patients with idiopathic pulmonary 
hypertension.10
Opitz et al described the long term clinical efﬁ  cacy of 
inhaled iloprost as ﬁ  rst-line monotherapy in patients with 
idiopathic PAH. In this study, only a minority of patients 
could be stabilized with inhaled iloprost monotherapy during 
a follow-up of up to 5 years. The authors concluded that 
chronic iloprost appears to have a limited role in the era of 
multiple treatment options.
Most recently, inhaled iloprost has been studied in patients 
who remain symptomatic (NYHA functional class III or IV) 
while on stable bosentan therapy for at least 3 months.31 In 
this multicenter, randomized controlled trial, 67 patients 
with PAH (94% NYHA functional class III, mean baseline 
6 minute walk distance 355 m) were randomized to receive 
inhaled iloprost or placebo. After 12 weeks, post-inhalation 
6 minute walk distance improved by 30 m in the iloprost group 
and 4 m in the placebo group, for a placebo-adjusted differ-
ence of +26 m (p = 0.051). There were also improvements in 
NYHA functional class (p = 0.002), time to clinical worsen-
ing (p = 0.022) and post-inhalation mean pulmonary arterial 
pressure (p  0.001), and pulmonary vascular resistance 
p  0.001). When assessing carefully these results, one can 
notice that the predeﬁ  ned signiﬁ  cance on the primary endpoint 
was not achieved. Moreover the clinical signiﬁ  cance of an 
increase of 26 m should be questioned. However, this study 
showed that combination therapy of inhaled iloprost appeared 
to be safe and well tolerated.
Even if strong scientiﬁ  c data are not available, clinical 
experience and current study results may lead to the con-
clusion that inhaled iloprost may not be ideal for ﬁ  rst-line 
monotherapy in chronic pulmonary hypertension. Its use in 
combination with other targeted therapy remains however 
of interest as there may be some synergism, for example 
with phosphodiesterase inhibitors (ie, sildenaﬁ  l), assuming 
that the latter may keep the levels of cAMP elevated in the 
cell and prolong or augment the effects of iloprost.32–35 This 
clearly requires further clinical studies.
Inhaled iloprost was approved by the FDA in 2004 
for functional class III and IV PAH, and in 2005 the 
indication was broadened to include add-on therapy for 
patients who remain symptomatic despite oral therapy 
with other agents.
When used chronically, inhaled iloprost may result in 
some side effects the most frequently reported in the adult 
population being ﬂ  ush, jaw pain, pain in lower extremities, 
headaches and diarrhea.
Although extensively studied in adults with PAH, less 
is known about the relative efﬁ  cacy of inhaled iloprost in 
children and experience has been limited, especially for 
prolonged therapy. We will now review this experience.
Dose and delivery in pediatrics
As mentioned, studies to evaluate delivery system and poten-
tial doses have essentially been performed in adults and there 
is clearly a lack of studies in the pediatric population. These 
are needed urgently. But as this disease is serious and life 
threatening, pediatricians have tried to extrapolate from adult 
studies on how to use inhaled iloprost in children.
Iloprost is available as single-use vials containing 
10 μg/mL either in a 1 mL or 2 mL aqueous solution. Indi-
cations approved are patients with idiopathic PAH NYHA 
class III in Europe (EMEA) and patients with PAH (group 
1 of Venice classiﬁ  cation) in NYHA class III and IV in the 
United States (FDA). For pediatrics, it is mentioned safety 
and efﬁ  cacy has not been established.
The recommended doses are 2.5 or 5 μg of inhaled 
iloprost starting with the low dose followed by the 5 μg for 
the second inhalation. Iloprost should not be taken less than 
6 times per day and up to 9 times are allowed. The maximal 
doses evaluated in trials were 45 μg per day.
Again no mention for speciﬁ  c dosages is available for 
pediatrics, as the drug is not approved for this population.
With regards to delivery devices, it is allowed or 
possible to use different devices providing that the droplets 
size is between 2.5 and 5 μm. In Europe, 4 devices are 
recommended for use: Venta-Neb™ (Nebutec Company, 
Elsenfeld, Germany), Halolite™, Pro-Dose™ AAD™ System, 
and I-Neb™ AAD™ System (all devices from Respironics Inc, 
Murrysville PA, USA). In the United States two devices are 
allowed the I-Neb™ ADD™ System and the Pro-Dose™ AAD™ 
System. Again no devices has been speciﬁ  cally tested in 
children
When the drug is applied to children older than 12 years 
and close to an adult weight an adult dose can be used; in 
smaller and younger patients physicians need to extrapolate 
the dose to be used in children. For delivery devices the rule 
of droplets size between 2.5 and 5 μm is true for children also. Vascular Health and Risk Management 2009:5 328
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However, depending on the age, clearly inhalation may be more 
problematic but we must remember that children with asthma or 
cystic ﬁ  brosis learn quite easily how to inhale at a very young 
age, and therefore inhalation may not be a major problem.
Chronic pulmonary hypertension
Several case reports reported the use of aerosolized iloprost 
in children. One of the ﬁ  rst clinical reports in a young patient 
was in 2001. A 5-year-old boy was treated with inhaled 
iloprost at a daily dose of 24 μg (6 times 4 μg). He showed 
continuous clinical improvement for three years while on 
therapy and avoided the use of continuous infusion of pros-
tacyclin for this period. No side effects were reported.36 The 
use of inhaled iloprost in combination with bosentan allowed 
to delaying lung transplantation in an 8-year-old boy.37 Aero-
solized iloprost was used a bridge to transplantation in young 
patients with cystic ﬁ  brosis.38 We can clearly not suggest that 
inhaled iloprost is beneﬁ  cial in young patients with cystic 
ﬁ  brosis but this case report raises the possibility of using 
this drug in patients with increased pulmonary pressure and 
cystic ﬁ  brosis. A study dedicated to this particular group of 
patients would be of major interest.
There is currently only one study showing the effect of 
chronic iloprost in a signiﬁ  cant number of pediatric patients.39 
Ivy et al examined the acute and chronic effects of inhaled 
iloprost in 23 children with idiopathic PAH or PAH associ-
ated with congenital heart disease. The dose applied ranged 
between 2.5 μg and 10 μg with 4 to 9 inhalations a day for 
a total daily dose of 3.75 to 50 μg, depending of the age and 
weight of the patients. No deﬁ  nite dosing for patient was dis-
cussed and no dose-ranging effect evaluation was performed 
during this study. The results show that 1) the acute pulmo-
nary vasodilator response to inhaled iloprost is equivalent to 
the effects of inhaled nitric oxide as measured during cardiac 
catheterization; 2) acute inhalation of iloprost can induce 
bronchoconstriction in some children, as demonstrated by 
cough and reductions in FEV1 and FEF25%–75% by pulmonary 
function tests; 3) the addition of inhaled iloprost therapy 
can reduce the need for intravenous prostanoid therapy in 
some patients; 4) most children tolerated the combination 
of inhaled iloprost and endothelin receptor antagonist or 
phosphodiesterase inhibitors. 5) Several patients had clini-
cal deterioration during chronic inhaled iloprost therapy and 
required rescue therapy with intravenous prostanoids.
Acute pulmonary hypertension
One of the major advantages of the inhalative approach is its 
selectivity for the pulmonary vascular bed. This is of major 
importance when used in acute pulmonary hypertensive crisis 
with hemodynamic compromise characterized by low sys-
temic pressure and low cardiac output. The minor effect on 
systemic pressure is here particularly beneﬁ  cial. Moreover, 
its intrapulmonary selectivity may improve ventilation/
perfusion mismatch and potentially oxygenation.
Inhaled iloprost was ﬁ  rst used in patients with acute 
respiratory failure and increased pulmonary arterial pressure 
accompanied by disturbances of gas exchange,40 then in acute 
heart right failure41 and later effects were compared with 
those of inhaled nitric oxide.42 All these different pathologies 
are encountered in pediatrics and thus these approaches have 
also been reported in children.
Several small studies have shown the potential efﬁ  cacy of 
inhaled iloprost in the acute pulmonary hypertension setting 
in pediatrics such as acute lung injury, post-cardiopulmonary 
bypass or in persistent pulmonary hypertension of the 
newborn.
De Luca et al reported two neonates treated with inhaled 
iloprost for persistent pulmonary hypertension of the neonate, 
one with diaphragmatic hernia and one associated with an 
aneurysm of the vein of Galien.43 Both patients were refrac-
tory to inhaled nitric oxide. Dose administered was 1 μg 
every 4 hours. They showed improvement in oxygenation. 
Chotigeat et al reported one case of persistent pulmonary 
hypertension of the neonate that had hypoxia despite high 
frequency oscillation, inotropic drugs and oral sildenaﬁ  l. 
Aerosolized iloprost was given trough the nasotracheal 
tube and induced signiﬁ  cant improvement in oxygenation.44 
Eiﬁ  nger et al treated 4 preterm neonates with 2 μg/kg iloprost 
per dose for a total of 44 to 65 doses in total. Oxygenation 
improved and echocardiography showed reduction in pul-
monary pressure.45
We are, however, still facing the same problem with these 
small case studies as no dose response or dose efﬁ  cacy has 
been reported and multiple different dosage are used which 
does not allow recommendations to be made for dose admin-
istration in this population. Moreover these patients were 
on spontaneous ventilation or intubated and ventilated with 
different modes of ventilation, which increases the difﬁ  culty 
of assessing the dose delivered to the patient.
Some studies have also presented the use of inhaled 
iloprost in acute pulmonary hypertension after cardiopul-
monary bypass for cardiac repair. Zwissler described the 
selective pulmonary vasodilatation of inhaled prostacyclin 
in a newborn after cardiopulmonary bypass.46 However, no 
large scale or randomized study has been performed in theses 
setting and it would be important to better assess the role of Vascular Health and Risk Management 2009:5 329
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this therapy in pediatric acute pulmonary hypertension and 
compare with the use of inhaled nitric oxide. An important 
aspect in acute patients is that all information on dosage is 
available in non-intubated patients and with delivery systems 
mentioned above; no real dose-ﬁ  nding studies or absorp-
tion studies have been conducted in intubated patients. It is 
not known how much drug is delivered to the patient and 
how much may be deposited in the nasotracheal tube for 
example. As such, caution should be the rule particularly in 
very young patients, and drug delivery in intubated patients 
should still be considered experimental. Studies should also 
aim to determine the dose and mode of delivery particularly 
in intubated patients.
Vasoreactivity testing
The assessment of pulmonary vascular reactivity plays an 
essential role in PAH. This is true for all forms of PAH to 
decide if, potentially, patients can be treated with calcium 
channel blockers in the so-called responders47 and also for 
PAH associated with congenital heart disease to decide for 
operability.48 A landmark study in adults showed that inhaled 
iloprost can be used for vasoreactivity testing and it was shown 
to be even more potent than inhaled nitric oxide.49 However, 
it may be of interest to perform a study similar to that of 
Sitbon to prove that acute effects of inhaled iloprost during 
acute testing can be translated to long term beneﬁ  cial effects 
of calcium channel blockers. We and others have shown that 
the response to inhaled nitric oxide seems to depend on the 
degree of pulmonary vascular disease and thus may be helpful 
in selecting patients for surgery.50,51 We have shown that in 
children with PAH and congenital heart disease, both inhaled 
nitric oxide and aerosolized iloprost are equally effective in 
selectively lowering pulmonary vascular resistance, both 
in the pre- and post-operative period using 25 ng/kg/min 
of iloprost.51 Halliloglu showed that both aerosolized and 
intravenous iloprost signiﬁ  cantly decreased in pulmonary 
pressure but aerosolized iloprost was more selective without 
decreasing systemic vascular pressure.52 Recently, Ivy et al 
showed that acute administration of inhaled iloprost lowered 
mean pulmonary artery pressure equivalent to the response 
to inhaled nitric oxide with oxygen.39 In this study the acute 
effects of inhaled iloprost were also assessed by pulmonary 
function prior to the initiation of chronic therapy and some 
patients presented signiﬁ  cant airways reactivity.
Summary and conclusion
Inhaled iloprost has been show to combine efﬁ  cacy with 
excellent tolerability and safety in the adult population. 
In several case series and case reports, similar results have 
been described in the pediatric population with more empha-
sis on acute pulmonary hypertension. The major drawbacks 
of this therapy remain the need for 6 to 9 inhalations a day, 
which if difﬁ  cult in an adult is even more complicated in a 
very young patient. But this is not the only problem, and 
speciﬁ  c studies in the pediatric population are required. 
They should better deﬁ  ne the dose for pediatric patients, if 
the use of the current devices to deliver iloprost in adults 
is also to be used in young patients. Currently strategies 
for further improvement that need to be studied in children 
include the use of controlled-released formulations (iloprost 
loaded liposomes) which may decrease the number of aerosol 
inhalations.
The current practice in children suggests that physicians 
choose ﬁ  rst an oral therapy, for practical reasons mainly and, 
as shown by the report of Ivy,39 inhaled iloprost is used as add 
on therapy because of inadequate response to oral treatment.
Signiﬁ  cant data are still lacking and speciﬁ  c studies in 
pediatric patients are urgently needed.
Disclosures
Professor Beghetti has served on a advisory boards for Pﬁ  zer, 
Actelion, Bayer-Schering, Encysive, GlaxoSmithKline, INO 
therapeutics, Eli Lilly and Mondobiotech, and has received 
lecture fees from Actelion, Encysive and Bayer-Schering.
References
  1.  Beghetti M. Congenital heart disease and pulmonary hypertension. Rev 
Port Cardiol. 2004;23(2):273–281.
  2.  Haworth SG. The management of pulmonary hypertension in children. 
Arch Dis Child. 2008;93(7):620–625.
  3.  Beghetti M. [Pulmonary arterial hypertension in children: new thera-
peutic approaches]. Ann Fr Anesth Reanim. 2007;26(6):570–575.
  4.  Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial 
hypertension. N Engl J Med. 200430;351(14):1425–1436.
 5. Rashid A, Ivy D. Severe paediatric pulmonary hypertension: new 
management strategies. Arch Dis Child. 2005;90(1):92–98.
  6.  Rosenzweig EB, Barst RJ. Pulmonary arterial hypertension in children: 
a medical update. Curr Opin Pediatr. 2008;20(3):288–293.
  7.  Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, 
et al. Guidelines on diagnosis and treatment of pulmonary arterial 
hypertension. The Task Force on Diagnosis and Treatment of Pulmo-
nary Arterial Hypertension of the European Society of Cardiology. 
Eur Heart J. 2004;25(24):2243–2278.
  8.  Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, 
et al. Treatment of primary pulmonary hypertension with continuous 
intravenous prostacyclin (epoprostenol). Results of a randomized trial. 
Ann Intern Med. 1990;112(7):485–491.
  9.  Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. 
Continuous subcutaneous infusion of treprostinil, a prostacyclin ana-
logue, in patients with pulmonary hypertension. Am J Respir Crit Care 
Med. 2002;165:1–5.
10.  Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, 
Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. 
N Engl J Med. 2002;347(5):322–329.Vascular Health and Risk Management 2009:5 330
Tissot and Beghetti
11.  Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, 
et al. Effects of the dual endothelin-receptor antagonist bosentan in patients 
with pulmonary hypertension: a randomised placebo-controlled study. 
Lancet. 2001;358(9288):1119–1123.
12.  Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. 
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 
2002;346(12):896–903.
13. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, 
et al. Ambrisentan for the treatment of pulmonary arterial hypertension: 
results of the ambrisentan in pulmonary arterial hypertension, random-
ized, double-blind, placebo-controlled, multicenter, efﬁ  cacy (ARIES) 
study 1 and 2. Circulation. 2008;117(23):3010–3019.
14.  Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, 
et al. Sildenaﬁ  l citrate therapy for pulmonary arterial hypertension. 
N Engl J Med. 2005;353(20):2148–2157.
15. Beghetti M. Current treatment options in children with pulmonary 
arterial hypertension and experiences with oral bosentan. Eur J Clin 
Invest. 2006;36 Suppl 3:16–24.
16.  Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. 
Outcomes in children with idiopathic pulmonary arterial hypertension. 
Circulation. 2004;110(6):660–665.
17.  Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pul-
monary hypertension in children. Circulation. 19;99(9):1197–1208.
18.  Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme iso-
lated from arteries transforms prostaglandin endoperoxides to 
an unstable substance that inhibits platelet aggregation. Nature. 
1976;263(5579):663–665.
19. Moncada S, Vane JR. Arachidonic acid metabolites and the inter-
actions between platelets and blood-vessel walls. N Engl J Med. 
1979;300(20):1142–1147.
20.  Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and 
pharmacokinetic properties, and therapeutic potential in peripheral 
vascular disease, myocardial ischaemia and extracorporeal circulation 
procedures. Drugs. 1992;43(6):889–924.
21.  Vane JR, Botting RM. Pharmacodynamic proﬁ  le of prostacyclin. Am J 
Cardiol. 1995;75(3):3A–10A.
22. Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, 
Schulz A, et al. Inhaled iloprost reverses vascular remodeling in chronic 
experimental pulmonary hypertension. Am J Respir Crit Care Med. 
2005;172(3):358–363.
23. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, 
Pullamsetti S, Weissmann N, et al. Antiremodeling effects of ilo-
prost and the dual-selective phosphodiesterase 3/4 inhibitor tolafen-
trine in chronic experimental pulmonary hypertension. Circ Res. 
2004;94(8):1101–1108.
24. Hildebrand M. Pharmacokinetics and tolerability of oral iloprost 
in thromboangiitis obliterans patients. Eur J Clin Pharmacol. 
1997;53(1):51–56.
25. Airo  P, Rossi M, Scarsi M, Danieli E, Grottolo A, Zambruni A. Disease-
modifying effects of long-term cyclic iloprost therapy in systemic 
sclerosis. A retrospective analysis and comparison with a control group. 
Clin Exp Rheumatol. 2007;25(5):722–727.
26.  Walmrath D, Schermuly R, Pilch J, Grimminger F, Seeger W. Effects 
of inhaled versus intravenous vasodilators in experimental pulmonary 
hypertension. Eur Respir J. 1997;10(5):1084–1092.
27.  Schermuly RT, Pullamsetti SS, Breitenbach SC, Weissmann N, 
Ghofrani HA, Grimminger F, et al. Iloprost-induced desensitization of 
the prostacyclin receptor in isolated rabbit lungs. Respir Res. 2007;8:4.
28.  Schermuly RT, Schulz A, Ghofrani HA, Breitenbach CS, Weissmann N, 
Hildebrand M, et al. Comparison of pharmacokinetics and vasodila-
tory effect of nebulized and infused iloprost in experimental pul-
monary hypertension: rapid tolerance development. J Aerosol Med. 
2006;19(3):353–363.
29.  Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, 
Hoper MM, et al. Inhaled iloprost to treat severe pulmonary hyperten-
sion. An uncontrolled trial. German PPH Study Group. Ann Intern Med. 
20;132(6):435–443.
30.  Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, 
Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary 
hypertension. Ann Intern Med. 1996;124(9):820–824.
31.  McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, 
et al. Randomized study of adding inhaled iloprost to existing bosen-
tan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 
2006;174(11):1257–1263.
32.  Schermuly RT, Krupnik E, Tenor H, Schudt C, Weissmann N, Rose F, 
et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances 
the pulmonary vasodilatory response to inhaled iloprost in experimental 
pulmonary hypertension. Maintenance of lung selectivity. Am J Respir 
Crit Care Med. 2001;164(9):1694–1700.
33. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, 
Kohstall M, et al. Zardaverine and aerosolised iloprost in a model of 
acute respiratory failure. Eur Respir J. 2003;22(2):342–347.
34.  Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, 
Kreckel A, et al. Oral sildenaﬁ  l as long-term adjunct therapy to inhaled 
iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 
2003;42(1):158–164.
35.  Schermuly RT, Ghofrani HA, Enke B, Weissmann N, Grimminger F, 
Seeger W, et al. Low-dose systemic phosphodiesterase inhibitors 
amplify the pulmonary vasodilatory response to inhaled prostacyclin 
in experimental pulmonary hypertension. Am J Respir Crit Care Med. 
19;160(5 Pt 1):1500–1506.
36. Beghetti M, Berner M, Rimensberger PC. Long term inhalation of 
iloprost in a child with primary pulmonary hypertension: an alternative 
to continuous infusion. Heart. 2001;86(3):E10.
37.  Beghetti M, Nicod L, Barazzone-Argiroffo C, Rimensberger PC. New 
combined treatments avoided transplantation in a child with severe 
pulmonary hypertension. Heart. 2004;90(2):154.
38. Tissieres P, Nicod L, Barazzone-Argiroffo C, Rimensberger PC, 
Beghetti M. Aerosolized iloprost as a bridge to lung transplantation in 
a patient with cystic ﬁ  brosis and pulmonary hypertension. Ann Thorac 
Surg. 2004;78(3):e48–e50.
39.  Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, 
et al. Short- and long-term effects of inhaled iloprost therapy in chil-
dren with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;
51(2):161–169.
40. Zwissler B, Kemming G, Habler o, Kleen M, Merkel M, Haller M, 
et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult 
respiratory distress syndrome. Am J Respir Crit Care Med. 1996;
154:1671–1677.
41.  Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Wollbruck B, 
Grimminger F, Seeger W. Recovery from circulatory shock in severe 
primary pulmonary hypertension (PPH) with aerosolization of iloprost. 
Intensive Care Med. 1998;24(6):631–634.
42. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, 
Hetzer R, et al. Assessment of the vasodilator response in primary pul-
monary hypertension. Comparing prostacyclin and iloprost administered 
by either infusion or inhalation. Eur Heart J. 2003;24(4):356–365.
43. De Luca D, Zecca E, Piastra M, Romagnoli C. Iloprost as ‘rescue’ 
therapy for pulmonary hypertension of the neonate. Paediatr Anaesth. 
2007;17(4):394–395.
44. Chotigeat U, Jaratwashirakul S. Inhaled iloprost for severe persis-
tent pulmonary hypertension of the newborn. J Med Assoc Thai. 
2007;90(1):167–170.
45. Eiﬁ  nger F, Sreeram N, Mehler K, Huenseler C, Kribs A, Roth B. 
Aerosolized iloprost in the treatment of pulmonary hypertension 
in extremely preterm infants: a pilot study. Klin Padiatr. 2008;
220(2):66–69.
46. Zwissler B, Rank N, Jaenicke U, Schürle B, Welte M, Reichart B, 
et al. Selective pulmonary vasodilation by inhaled prostacyclin in a 
newborn with congenital heart disease and cardiopulmonary bypass. 
Anesthesiology. 1995;82:1512–1516.
47.  Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, et al. 
Inhaled nitric oxide as a screening vasodilator agent in primary pulmo-
nary hypertension. Am J Respir Crit Care Med. 1995;151:384–389.Vascular Health and Risk Management 2009:5 331
Inhaled iloprost in children
48.  Roberts JD Jr, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. 
Inhaled nitric oxide in congenital heart disease. Circulation. 1993;
87(2):447–453.
49. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, 
Borst MM, et al. A comparison of the acute hemodynamic effects of 
inhaled nitric oxide and aerosolized iloprost in primary pulmonary 
hyper  tension. German PPH study group. J Am Coll Cardiol. 20;35(1):
176–182.
50.  Berner M, Beghetti M, Spahr-Schopfer I, Oberhansli I, Friedli B. 
Inhaled nitric oxide to test the vasodilator capacity of the pulmonary 
vascular bed in children with long-standing pulmonary hypertension 
and congenital heart disease. Am J Cardiol. 1996;77(7):532–535.
51.  Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, 
Friedli B, et al. Inhaled nitric oxide versus aerosolized iloprost in 
secondary pulmonary hypertension in children with congenital heart 
disease: vasodilator capacity and cellular mechanisms. Circulation. 
2001;103(4):544–548.
52.  Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic 
effects of aerosolized and intravenous iloprost in secondary pulmonary 
hypertension in children with congenital heart disease. Am J Cardiol. 
2003;92(8):1007–1009.